| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 481.00M | — |
| Operating expense | — | — |
| Net income | 229.91M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, RV7.F returned +51.6% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +59.4% |
| 1 year | +51.6% |
| 5 years | +162.1% |
| 10 years | +1427.0% |
| All-time high | €92.84 (Aug 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in RV7.F would be worth today ›No. Halozyme Therapeutics, Inc. has not paid a dividend in the past 12 months.
Halozyme Therapeutics, Inc. is part of the Healthcare sector.
Halozyme Therapeutics, Inc. has a market cap of 10.54B EUR, based on the latest quote.
Halozyme Therapeutics, Inc. is expected to report earnings around Nov 2, 2026. That date is an estimate and has not been confirmed by the company.
